article thumbnail

How Amazon could Disrupt Pharmacy Services

The Digital Apothecary

Personally, I haven't seen this much attention in awhile about pharmacy since PillPack made strip-packaging of medications mainstream three-years ago, and am quite eager to see if this is really going to change the current paradigm of pharmacy services. One issue is that the dispensing process is not a full-proof system at the current time.

article thumbnail

Clinical trials for rare diseases

European Pharmaceutical Review

How does the qualification package support more meaningful endpoints and rare disease research as a result? Because the submission of the plan will open this dialogue, it will also socialise these issues with other rare disease populations and provide the opportunity to mitigate them in their own communities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NHC Comments on Medicare Prescription Payment Plan

Putting Patients First Blog

The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. It is vital that communication, both for beneficiaries and for health care providers and pharmacists, adhere to these principles.

article thumbnail

NHC Comments on Medicare Prescription Payment Plan

Putting Patients First Blog

The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. It is vital that communication, both for beneficiaries and for health care providers and pharmacists, adhere to these principles.

article thumbnail

How early planning leads to successful market access and drug launch in Europe

Pharmaceutical Technology

Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. Meanwhile, in Germany, the AMNOG process is conducted twelve months after the drug is launched, thus giving freedom to the company to set the drug’s price during this period.